Logo
Home
Company ProfileBoards & StaffsMemberships & PartnersAcademy of JournalismCareersBlog(EN)Contact Us
Our JournalsInstruction for AuthorsBrieflands PoliciesPublish My ResearchJournal Management SystemArticle Processing ChargesOpen Peer ReviewPublishing Services
Publish My Book
  1. Brieflands
  2. journals
  3. Journal of Advanced Immunopharmacology
  4. Articles

  5. Bebtelovimab: The FDA-approved Monoclonal Antibody for Treating Patients with Mild-to-Moderate COVID-19
  6. Crossref

Journal of Advanced Immunopharmacology

Home
Current IssueArchiveIn PressAccepted ManuscriptsSearch
Instruction
Journal InformationBoards and EditorsIndexing and Listing SourcesJournal MetricsOpen Peer Review (OPR)Publication Ethics and Malpractice StatementReviewer and AE Registration FormAnnouncement: New Journal TitleSupportContact Us
Authors GuideSubmit Manuscript

Crossref


1. Unlocking the potential of in silico approach in designing antibodies against SARS-CoV-2

- Tasshitra Subramaniam

- Siti Aisyah Mualif

- Weng Howe Chan

- Khairul Bariyyah Abd Halim

2. Lessons we learned during the past four challenging years in the COVID-19 era: pharmacotherapy, long COVID complications, and vaccine development

- Parisa Ghasemiyeh

- Soliman Mohammadi-Samani

HomeInstruction

Articles

  • Current Issue
  • Archive
  • In Press
  • Accepted Manuscripts
  • Search

About Journal

  • Journal Information
  • Boards and Editors
  • Indexing and Listing Sources
  • Journal Metrics
  • Open Peer Review (OPR)
  • Publication Ethics and Malpractice Statement
  • Reviewer and AE Registration Form
  • Announcement: New Journal Title
  • Support
  • Contact Us
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.